Scott Fretzin

1.7k total citations
14 papers, 1.0k citations indexed

About

Scott Fretzin is a scholar working on Dermatology, Immunology and Surgery. According to data from OpenAlex, Scott Fretzin has authored 14 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Dermatology, 9 papers in Immunology and 2 papers in Surgery. Recurrent topics in Scott Fretzin's work include Psoriasis: Treatment and Pathogenesis (9 papers), Dermatology and Skin Diseases (7 papers) and Colorectal and Anal Carcinomas (2 papers). Scott Fretzin is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (9 papers), Dermatology and Skin Diseases (7 papers) and Colorectal and Anal Carcinomas (2 papers). Scott Fretzin collaborates with scholars based in United States, Canada and United Kingdom. Scott Fretzin's co-authors include Alan Menter, Alice B. Gottlieb, Rod Kunynetz, Arthur Kavanaugh, Yaung‐Kaung Shen, Alan M. Mendelsohn, Cynthia Guzzo, Shu Li, Patrick Haslett and Juliet McColm and has published in prestigious journals such as The Lancet, Journal of Allergy and Clinical Immunology and Gene.

In The Last Decade

Scott Fretzin

13 papers receiving 992 citations

Peers

Countries citing papers authored by Scott Fretzin

Since Specialization

Citations

This map shows the geographic impact of Scott Fretzin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Fretzin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Fretzin more than expected).

Fields of papers citing papers by Scott Fretzin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Fretzin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Fretzin. The network helps show where Scott Fretzin may publish in the future.

Co-authorship network of co-authors of Scott Fretzin

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Fretzin. A scholar is included among the top collaborators of Scott Fretzin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Fretzin. Scott Fretzin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-Controlled Study (PSORIATYK SCALP) 2025 ·SKIN The Journal of Cutaneous Medicine ·Linda Stein Gold, Michael Sebastian, (unknown), Brandon Becker, Yichen Zhong, (unknown), Michael DeRosa, Scott Fretzin, Andreas Pinter, C.E.M. Griffiths	0
2	Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study 2025 ·Journal of the American Academy of Dermatology ·Lindsay Ackerman, Bethanee J. Schlosser, Tianyu Zhan, Vimal H. Prajapati, Scott Fretzin, Hidetoshi Takahashi, Xiaohong Huang, Heidi S. Camp, Alexa B. Kimball	5
3	43799 Efficacy and Safety of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Study 2023 ·Journal of the American Academy of Dermatology ·Alexa B. Kimball, Lindsay Ackerman, Bethanee J. Schlosser, Vimal H. Prajapati, Scott Fretzin, Hidetoshi Takahashi, Tianyu Zhan, Xiaohong Huang, Heidi S. Camp	15
4	Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study 2022 ·Journal of Cutaneous Medicine and Surgery ·David Rosmarin, Scott Fretzin, Lindsay C. Strowd, Marta Casillas, Amy M. DeLozier, (unknown), (unknown), Na Lü, Jacob P. Thyssen	4
5	Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Whose Disease Did Not Respond to Prior Biologics 2019 ·SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Lawrence Green, (unknown), Scott Fretzin, Abby Jacobson	1
6	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis 2018 ·British Journal of Dermatology ·Caitriona Ryan, Alan Menter, Lyn Guenther, Andrew Blauvelt, Robert Bissonnette, K.A.P. Meeuwis, John Sullivan, Jennifer Clay Cather, Gil Yosipovitch, Alice B. Gottlieb, Joseph F. Merola, Kristina Callis Duffin, Scott Fretzin, Olawale Osuntokun, Russel Burge, April N. Naegeli, Fan Emily Yang, Chen‐Yen Lin, (unknown), Alison Potts Bleakman, (unknown)	85
7	Patients’ Perspectives on the Impact of Genital Psoriasis: A Qualitative Study 2017 ·Dermatology and Therapy ·Jennifer Clay Cather, Caitriona Ryan, K.A.P. Meeuwis, (unknown), April N. Naegeli, Emily Edson‐Heredia, Jiat Ling Poon, (unknown), (unknown), Lyn Guenther, Scott Fretzin	44
8	Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis 2016 ·Journal of Dermatological Treatment ·Neil J. Korman, Howard Sofen, Scott Fretzin, Phoebe Rich, Yang Zhao, Vivian Herrera, Judit Nyirady, Nicole Williams, Margaret Mordin, Stephen K. Tyring	14
9	IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis 2012 ·Journal of Allergy and Clinical Immunology ·James G. Krueger, Scott Fretzin, Mayte Suárez‐Fariñas, Patrick Haslett, Krista M Phipps, Gregory S. Cameron, Juliet McColm, (unknown), Inna Cueto, (unknown), Subhashis Banerjee, Robert W. Hoffman	300
10	Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial 2009 ·The Lancet ·Alice B. Gottlieb, Alan Menter, Alan M. Mendelsohn, Yaung‐Kaung Shen, Shu Li, Cynthia Guzzo, Scott Fretzin, Rod Kunynetz, Arthur Kavanaugh	446
11	Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial 2006 ·International Journal of Dermatology ·Kim Papp, (unknown), Scott Fretzin, Bernard S. Goffe, Steven Kempers, Kenneth B. Gordon, Ivor Caro, Patricia A. Walicke, Xiaolin Wang, Alan Menter, (unknown)	55
12	Successful treatment of hand and foot psoriasis with efalizumab therapy. 2006 ·PubMed ·Scott Fretzin, Jeffrey Crowley, (unknown), Melodie Young, Jeffrey M. Sobell	14
13	Ignition Potential of the 585-nm Pulsed-Dye Laser 1996 ·Dermatologic Surgery ·Scott Fretzin, William H. Beeson, WILLIAM C. HANKE	11
14	A Drosophila melanogaster H3.3 cDNA encodes a histone variant identical with the vertebrate H3.3 1991 ·Gene ·Scott Fretzin, (unknown), Angela van Daal, Sarah C. R. Elgin	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact